Cover image for Vol. 119 Issue 15

1 August 2013

Volume 119, Issue 15

Pages 2665–2815

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. Surgery versus stereotactic radiotherapy for patients with early-stage non–small cell lung cancer: More data from observational studies and growing clinical equipoise (pages 2668–2670)

      Suresh Senan

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28101

      This study of outcomes after either surgery or stereotactic ablative radiotherapy for patients with early-stage non–small cell lung cancer found that overall survival was correlated only with the Charlson Comorbidity Index, and that only tumor diameter was correlated with locoregional tumor control. These findings will increase clinical equipoise and facilitate patient inclusion into ongoing trials comparing both treatments.

    2. CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia (pages 2671–2674)

      Dieter Hoelzer

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28135

      Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 (pages 2675–2682)

      Alvaro Moreno-Aspitia, David W. Hillman, Stephen H. Dyar, Kathleen S. Tenner, Julie Gralow, Peter A. Kaufman, Nancy E. Davidson, Jacqueline M. Lafky, Monica M. Reinholz, Wilma L. Lingle, Leila A. Kutteh, Walter P. Carney, Amylou C. Dueck and Edith A. Perez

      Article first published online: 6 JUN 2013 | DOI: 10.1002/cncr.28130

      There is great interest in finding biomarkers that can potentially prognosticate the risk of disease recurrence and predict the response to antihuman epidermal growth factor receptor 2 (HER2)-based therapies in early stage HER2-positive breast cancer. In the current study, the authors identify the soluble HER2 (sHER2) level as a prognostic marker associated with shorter disease-free survival and a high recurrence rate.

    2. Chest and Lung Disease
      Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non–small cell lung cancer treated with resection or stereotactic radiosurgery (pages 2683–2691)

      John Varlotto, Achilles Fakiris, John Flickinger, Laura Medford-Davis, Adam Liss, Julia Shelkey, Chandra Belani, Jill DeLuca, Abram Recht, Neelabh Maheshwari, Robert Barriger, Nengliang Yao and Malcolm DeCamp

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28100

      Stereotactic Body Radiotherapy (SBRT) is an alternative to surgery for clinical Stage I non–small cell lung cancer. Our retrospective investigation demonstrates similar overall survival, locoregional control, and total recurrence control with surgery or SBRT after controlling for prognostic and patient selection factors.

    3. Gastrointestinal Disease
      A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer (pages 2692–2700)

      Edward J. Kim, Edgar Ben-Josef, Joseph M. Herman, Tanios Bekaii-Saab, Laura A. Dawson, Kent A. Griffith, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Theodore S. Lawrence, Daniel Laheru, Christopher L. Wolfgang, Terence Williams, Mark Bloomston, Malcolm J. Moore, Alice Wei and Mark M. Zalupski

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28117

      Preoperative therapy with full-dose gemcitabine, oxaliplatin, and radiotherapy is feasible in patients with pancreatic cancer and results in a high percentage of complete resections. These results are particularly encouraging because the majority of patients had borderline resectable disease.

    4. Head and Neck Disease
      Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients (pages 2701–2709)

      Aidin Kashigar, Steven Habbous, Lawson Eng, Brendan Irish, Eric Bissada, Jonathan Irish, Dale Brown, Ralph Gilbert, Patrick Gullane, Wei Xu, Shao-Hui Huang, Ian Witterick, Jeremy Freeman, Brian O'Sullivan, John Waldron, Geoffrey Liu and David Goldstein

      Article first published online: 13 JUN 2013 | DOI: 10.1002/cncr.28088

      Smoking cessation following a diagnosis of head and neck cancer was strongly associated with lack of exposure to cigarette smoke at home, from one's spouse, from one's peers, and with more frequent visitation to one's family physician. Smoking cessation interventions should consider these factors to improve quitting rates.

    5. Hematologic Malignancies
      Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1–infected patients: A matched cohort study (pages 2710–2719)

      Vincenzo Spagnuolo, Giovanna Travi, Laura Galli, Francesca Cossarini, Monica Guffanti, Nicola Gianotti, Stefania Salpietro, Adriano Lazzarin and Antonella Castagna

      Article first published online: 26 APR 2013 | DOI: 10.1002/cncr.28119

      Human immunodeficiency virus (HIV)-infected lymphoma survivors reach long-term immune recovery and virologic suppression similar to what is observed in cancer-free, HIV-infected patients. Clinical events are more common among lymphoma survivors, especially during the first year of follow-up.

    6. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades (pages 2720–2727)

      Mya S. Thein, William B. Ershler, Ahmedin Jemal, Jerome W. Yates and Maria R. Baer

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28129

      The survival of older adults with acute myeloid leukemia remains poor, but has improved in patients up to age 75 years. The current data support the importance of recognizing clinically relevant differences between “younger old” and “older old” patients.

    7. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia (pages 2728–2736)

      Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Partow Kebriaei, Elias Jabbour, Michael Rytting, Sergernne York, Farhad Ravandi, Rebecca Garris, Monica Kwari, Stefan Faderl, Jorge Cortes, Richard Champlin and Susan O'Brien

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28136

      Inotuzumab single-agent therapy is highly active, safe, and convenient in refractory-relapsed acute lymphocytic leukemia. A weekly dose schedule appears to be equally effective and less toxic than a single-dose schedule.

    8. Melanoma
      Pathologic and gene expression features of metastatic melanomas to the brain (pages 2737–2746)

      Ronald Hamilton, Michal Krauze, Marjorie Romkes, Bernard Omolo, Panagiotis Konstantinopoulos, Todd Reinhart, Malgorzata Harasymczuk, YangYang Wang, Yan Lin, Soldano Ferrone, Theresa Whiteside, Stephanie Bortoluzzi, Jonette Werley, Tomoko Nukui, Beth Fallert-Junecko, Douglas Kondziolka, Joseph Ibrahim, Dorothea Becker, John Kirkwood and Stergios Moschos

      Article first published online: 21 MAY 2013 | DOI: 10.1002/cncr.28029

      Metastatic melanomas to the brain are more similar to extracranial metastases compared with primary melanomas. Metastatic melanoma to the brain has a variable prognosis: low or absent intratumoral hemorrhage and high mononuclear infiltrate define a subgroup with favorable prognosis.

    9. Discipline

      Clinical Trials
      Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma (pages 2747–2753)

      Shlomit Yust-Katz, Diane Liu, Ying Yuan, Vivien Liu, Sanghee Kang, Morris Groves, Vinay Puduvalli, Victor Levin, Charles Conrad, Howard Colman, Sigmonid Hsu, W. K. Alfred Yung and Mark R. Gilbert

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28031

      Lonafarnib, an oral selective farnesyltransferase inhibitor, can be safely combined with temozolomide. This combination is effective in patients with recurrent glioblastoma.

    10. Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study (pages 2754–2764)

      Athanasios Karampeazis, Alexandra Voutsina, John Souglakos, Nikos Kentepozidis, Stelios Giassas, Charalambos Christofillakis, Athanasios Kotsakis, Pavlos Papakotoulas, Ageliki Rapti, Maria Agelidou, Sofia Agelaki, Lambros Vamvakas, George Samonis, Dimitris Mavroudis and Vassilis Georgoulias

      Article first published online: 9 MAY 2013 | DOI: 10.1002/cncr.28132

      Both pemetrexed and erlotinib are active in patients with pretreated non–small cell lung cancer (NSCLC). In this randomized controlled phase 3 trial, the 2 drugs are compared, and the results indicate that both agents are equally effective in unselected patients with previously treated NSCLC, although they have different toxicity profiles. Exploratory biomarker analyses indicate no difference in efficacy irrespective of EGFR status, whereas the presence of KRAS mutations is correlated with treatment efficacy.

    11. Medical Oncology
      Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas (pages 2765–2770)

      Frank A. Sinicrope, Thomas C. Smyrk, David Tougeron, Stephen N. Thibodeau, Shalini Singh, Andrea Muranyi, Kandavel Shanmugam, Thomas M. Grogan, Steven R. Alberts and Qian Shi

      Article first published online: 8 MAY 2013 | DOI: 10.1002/cncr.28133

      Immunohistochemical analysis of mutant (substitution of valine by glutamic acid at position 600 [V600E]) v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) protein expression yields highly concordant results with a DNA-based assay for the detection of BRAFV600E mutations in human colon carcinomas. This finding suggests that immunohistochemistry is an alternative approach for detecting BRAFV600E mutations in clinical practice.

    12. Outcomes Research
      Outcomes in stage I testicular seminoma: A population-based study of 9193 patients (pages 2771–2777)

      Clair J. Beard, Lois B. Travis, Ming-Hui Chen, Nils D. Arvold, Paul L. Nguyen, Neil E. Martin, Deborah A. Kuban, Andrea K. Ng and Karen E. Hoffman

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28086

      Despite high cure rates following treatment for stage I testicular seminoma, survivors experience increased all-cause mortality and mortality from second malignant neoplasms and suicide but not cardiovascular disease following modern radiotherapy. The absolute risk of second malignancies is lower than reported in older series.

    13. Pathology
      Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases (pages 2778–2788)

      Antoine Brouquet, Giuseppe Zimmitti, Scott Kopetz, Judith Stift, Catherine Julié, Anne-Isabelle Lemaistre, Atin Agarwal, Viren Patel, Stephane Benoist, Bernard Nordlinger, Alessandro Gandini, Michel Rivoire, Stefan Stremitzer, Thomas Gruenberger, Jean-Nicolas Vauthey and Dipen M. Maru

      Article first published online: 23 APR 2013 | DOI: 10.1002/cncr.28097

      Pathologic response and tumor thickness at the tumor-normal interface are reproducible criteria that may be used in routine clinical practice and are new end points for the assessment of biomarkers of chemotherapy response in colorectal liver metastases.

    14. Pediatric Oncology
      Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody (pages 2789–2795)

      Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Kim Kramer and Nai-Kong V. Cheung

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28137

      Posterior reversible encephalopathy syndrome (PRES) is associated with immunotherapy using antidisialoganglioside (anti-GD2) monoclonal antibody, which is now standard for high-risk neuroblastoma, but has not previously been implicated in PRES. Patients receiving this treatment should be closely monitored for, and undergo immediate treatment or evaluation of, symptoms (eg hypertension or headaches) that may herald PRES.

    15. Psychosocial Oncology
      Uncertainty, mood states, and symptom distress in patients with primary brain tumors: Analysis of a conceptual model using structural equation modeling (pages 2796–2806)

      Lin Lin, Hui-Hsun Chiang, Alvina A. Acquaye, Elizabeth Vera-Bolanos, Mark R. Gilbert and Terri S. Armstrong

      Article first published online: 9 MAY 2013 | DOI: 10.1002/cncr.28121

      Illness-related uncertainty is a significant psychological experience for patients with primary brain tumors. It may be possible to lessen perceived symptoms by reducing uncertainty in patients with primary brain tumors and promoting more positive mood states.

    16. Radiation Oncology
      Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity (pages 2807–2814)

      Abhishek A. Solanki and Stanley L. Liauw

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28128

      The effect of tobacco use on disease control and late toxicity in men treated with dose-escalated external beam radiotherapy for prostate cancer has not been well-defined. Tobacco use was not independently associated with biochemical failure or gastrointestinal toxicity, but a history of tobacco use was associated with worse late grade ≥2 genitourinary toxicity and current smokers had worse late grade ≥3 genitourinary toxicity compared with prior and never smokers.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. Is 20% of a loaf enough? (page 2815)

      Robert P. Young and Raewyn J. Hopkins

      Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28134